

**ANALYTICAL METHOD VALIDATION COMMITTEE FOR NON
PHARMACOPOEIAL PRODUCT
DEPARTMENT OF DRUG ADMINISTRATION
National Medicines Laboratory**

Esomeprazole Fast Releasing Tablets

Analytical Profile No.: Esmo FR 076/077/061

Esomeprazole Fast Releasing Tablets contain not less than 90% and not more than 110% of the stated amount of Esomeprazole.

1. Identification:

In the assay, the principle peak in the chromatogram obtained with the sample solution should correspond to the peak in the chromatogram obtained with the reference standard solution of Esomeprazole.

2. Dissolution: *By liquid chromatography*

2.1 Dissolution Parameters:

Apparatus: Paddle

Medium: 900 ml of phosphate buffer pH 7.4 prepared by dissolving 40.8 g of potassium dihydrogen orthophosphate and 9.36 g of sodium hydroxide in 6000 ml of water, mixing properly and adjusting pH 7.4 with sodium hydroxide or potassium dihydrogen orthophosphate.

Speed and Time: 75 rpm & 30 minutes

Withdraw a suitable volume of the medium and filter.

Determine by liquid chromatography.

2.2 Test Solution: Dilute 5 ml of the filtrate to 10 ml with dissolution media. Finally filter through 0.2 µm membrane filter paper.

2.3 Reference Solution:

Transfer carefully about 23 mg of *Esomeprazole Magnesium WS* into 100 ml volumetric flask and dissolve with 10 ml of methanol and finally make up the volume with dissolution media. Further dilute 5 ml of this solution to 50 ml with the dissolution media and filter through 0.2 µm membrane filter paper.

2.4 Procedure:

Use the chromatographic system as described in the Assay using 20µl as injection volume.

Inject the reference solution and the test solution. Measure the peak responses and calculate the % release of the drug.

**ANALYTICAL METHOD VALIDATION COMMITTEE FOR NON
PHARMACOPOEIAL PRODUCT
DEPARTMENT OF DRUG ADMINISTRATION
National Medicines Laboratory**

2.5 Limit:

D. Not less than 75.0 % of the stated amount of Esomeprazole.

3. Uniformity of content

Determine by liquid chromatography, as described in the Assay, using the following solution as the test solution.

Test solution: Weigh 10 tablets and transfer each into 100 ml volumetric flask. Add 70 ml of solvent mixture shake to disperse, sonicate for 15 minutes; cool and make up the volume to the mark with solvent mixture. Centrifuge the solution at 2000 rpm for 10 minutes and further dilute 5 ml of this solution to 50 ml with the mobile phase. Finally filter the solution through 0.2 micron filter paper.

4. Assay: *Determine by liquid chromatography*

4.1 Solvent Mixture: Methanol

4.2 Test Solution: Determine the average weight of 20 tablets. Crush them into homogeneous mixture in mortar and pestle. Transfer carefully powder equivalent to 40 mg of Esomeprazole into 100 ml volumetric flask, add 70 ml of solvent mixture, shake gently to disperse, sonicate for 15 minutes, cool and make up the volume to the mark with solvent mixture. Centrifuge the solution at 2000 rpm for 10 minutes and further dilute 5 ml of the solution to 50 ml with the mobile phase.

4.3 Reference Solution: Transfer carefully about 44 mg of *Esomeprazole Magnesium WS* into 100 ml volumetric flask. Add 70 ml of solvent mixture, shake for few minutes and sonicate for 5 minutes; cool and make up the volume to 100 ml with the solvent mixture. Further dilute 5 ml of this solution to 50 ml with the mobile phase.

4.4 Chromatographic system:

- **Column:** Octylsilane (C8), (150x4.6 mm), 5 µm
- **Wavelength:** 300 nm
- **Flow rate:** 1.0 ml/min
- **Injection volume:** 10 µl
- **Column Temperature:** Ambient
- **Detector:** UV

**ANALYTICAL METHOD VALIDATION COMMITTEE FOR NON
PHARMACOPOEIAL PRODUCT
DEPARTMENT OF DRUG ADMINISTRATION
National Medicines Laboratory**

- **Mobile Phase:** A mixture of equal volume of methanol and buffer solution prepared by dissolving 6.8 g of potassium dihydrogen phosphate and about 1 g of sodium hydroxide in 1000 ml of water, and adjusting pH to 7.0 with orthophosphoric acid.

4.5 Procedure: Inject the reference solution five/six times and sample solutions. The test is not valid unless the column efficiency is not less than 2000 theoretical plates. The tailing factor is not more than 2.0 and the relative standard deviation for replicate injections is not more than 2.0%. Measure the peak responses. Calculate the content of Esomeprazole in the tablet.

5. Other tests: As per pharmacopoeial requirements.